| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | pandacostat | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | 0.03 | 0.8 |